Project Grant R41AG092199
Award Date 9/20/25
Completion Date 9/19/27
Dollars Obligated $252K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Latham, NY 12110, USA
Similar Awards
- The National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, awarded a $1,249,957 Project Grant under CFDA 93.866 (Aging Research) to Advantage Therapeutics, Inc. in Florida. The grant aims to perform IND-enabling studies on a small molecule that is disease-modifying, low-cost, and has a long safety record for the treatment of Alzheimer's disease. The proposed molecule is designed to reduce brain inflammation and restore phagocytosis, thereby improving the...
- This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $499,441 to Acepre, LLC to develop a novel brain-targeted delivery system for the compound N-acetylcysteine (TN-NAC) as a potential treatment for Alzheimer's disease (AD). The key objectives of this Phase I STTR study are to: 1) evaluate the toxicity and pharmacokinetic properties of TN-NAC in mice, and 2) test the therapeutic efficacy of TN-NAC in a 3xTG-AD mouse model of...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development of a novel Alzheimer's disease therapeutic using targeted nanoparticles. The $504,732 award to Aphios Corp, a minority-owned biotechnology company, will support two phases of research. In Phase I, the company will nanoencapsulate an anti-CCR5 drug in targeted and non-targeted nanoparticles, characterize the formulations, and evaluate their impact on in vitro models of brain...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,883 to Degrome Therapeutics, Inc. to develop small-molecule degraders of the amyloid precursor protein (APP) as novel therapeutics for Alzheimer's disease (AD). The project aims to optimize lead APP degrader compounds to improve their potency, solubility, and blood-brain barrier permeability, with the goal of identifying the most promising candidates for further development and evaluation...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,012,534 to Eydis Bio, Inc. to develop orally bioavailable and blood-brain barrier penetrant, small molecule TAK1 inhibitors as a novel treatment for Alzheimer's disease. The Phase I STTR grant supports identifying suitable TAK1 inhibitors with optimal central nervous system blood-brain barrier penetrance that can be further advanced into in vivo testing in the PS19 mouse model. The goal is to...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $258,213 to Reelin Therapeutics, Inc. to identify the next generation of gamma-secretase modulators for the treatment of Alzheimer's disease. The research aims to develop novel lead compounds that can lower amyloid-beta 42 production, a key driver of amyloid plaque formation, while avoiding effects on other gamma-secretase substrates like Notch. Through medicinal chemistry and in vitro/in vivo...
- This Project Grant award of $475,014.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a novel neurotrophic therapeutic for treating the cognitive deficits associated with Alzheimer's disease. The key products and services to be delivered through this grant include: Scaling up the production of a recombinant, non-erythropoietic neurotrophic protein that has demonstrated cognitive enhancement effects in Alzheimer's disease models. Evaluating the toxicity...
- This Project Grant award from the National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), will support the lead optimization of a therapeutic candidate for Alzheimer's disease (AD). The $349,605 award to Stress Therapeutics, Inc., a California-based biopharmaceutical company, aims to advance the development of a first-in-class treatment that can reduce hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis, a key pathogenic driver of AD...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $994,436.00 to Transchromix LLC to develop novel brain-penetrant drugs for treating Alzheimer's disease (AD). The key products and services being delivered include: Discovering a noncanonical, translation regulatory function of the histone methyltransferase G9A in AD pathogenesis using a chromatin-activity-based chemoproteomic (ChAC) approach to dissect AD heterogeneity. Deducing the mechanism...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...